Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768558 · ClinicalTrials.gov registry record · Phase 3
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
A Phase 3 study, sponsored by RTOG Foundation.
- Terminated
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
NCT02768558 is a Phase 3 study that was terminated before completion, run by RTOG Foundation. The registered enrollment target is 20 participants.
The verdict
NCT02768558, a Phase 3 study, was terminated before completion, sponsored by RTOG Foundation.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
Study Summary
Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.
Interventions
- DRUG Cisplatin
- OTHER Placebo
- DRUG Nivolumab
- DRUG Etoposide
- RADIATION Radiation Therapy (RT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2016-10-17 |
| Est. Completion | 2019-01-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02768558
The ClinicalTrials.gov registry entry for NCT02768558 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RTOG Foundation, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT02768558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02768558 about?
NCT02768558 is a clinical study titled "Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC". Patients with Stage III unresectable non-small cell lung cancer will receive thoracic radiation, cisplatin and etoposide followed by nivolumab or placebo given every 2 weeks for a year.
What is the current status of trial NCT02768558?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2016-10-17. Estimated completion is 2019-01-23.
What interventions are being tested in trial NCT02768558?
The interventions under investigation include: Cisplatin (DRUG), Placebo (OTHER), Nivolumab (DRUG), Etoposide (DRUG), Radiation Therapy (RT) (RADIATION).
Who is sponsoring clinical trial NCT02768558?
This trial is sponsored by RTOG Foundation, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.